Jul 10, 2023 / 02:25PM GMT
Yaron Benjamin Werber - TD Cowen, Research Division - MD & Senior Biotechnology Analyst
Well, good morning, everybody, and thank you for joining us for our 2nd RNA Summit. I'm Yaron Werber, on the biotech team here at TD Cowen, and it's a great pleasure to moderate the next session with Ionis Pharmaceuticals with Brett Monia, who is the Chief Executive Officer.
Brett, good morning. Right and early on your side. Thanks for joining us.
Brett P. Monia - Ionis Pharmaceuticals, Inc. - Founder, CEO & Director
Good morning, Yaron. it's a pleasure to be here.
Questions and Answers:
Yaron Benjamin Werber - TD Cowen, Research Division - MD & Senior Biotechnology AnalystSo lots to talk about. I want to kick off with eplontersen, especially on the heels of the 85 week data was literally which just got presented showing a nice sustainability now we've seen from 35 weeks to 66 weeks, and now to 85 weeks on TTR reduction and clinical outcomes as well. The PDUFA is coming up in December for TTR
Trustpilot
